MGO One Seven LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

MGO One Seven LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 64.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,401 shares of the company's stock after purchasing an additional 4,469 shares during the period. MGO One Seven LLC's holdings in Zoetis were worth $1,858,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ZTS. Mission Wealth Management LP increased its holdings in shares of Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after acquiring an additional 59 shares during the last quarter. VeraBank N.A. boosted its holdings in Zoetis by 4.1% in the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company's stock valued at $254,000 after purchasing an additional 62 shares in the last quarter. HUB Investment Partners LLC increased its stake in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after purchasing an additional 62 shares during the last quarter. Procyon Advisors LLC raised its holdings in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock worth $768,000 after purchasing an additional 63 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators raised its holdings in Zoetis by 6.6% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock worth $170,000 after purchasing an additional 65 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

Shares of NYSE:ZTS traded up $1.28 during trading on Friday, reaching $153.58. The company had a trading volume of 3,543,605 shares, compared to its average volume of 2,501,356. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The stock's fifty day moving average price is $158.91 and its 200 day moving average price is $168.32. The firm has a market capitalization of $68.52 billion, a price-to-earnings ratio of 28.08, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.30%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio is presently 36.56%.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,862 shares of company stock worth $312,254. Company insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ZTS. Morgan Stanley dropped their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Piper Sandler raised their price objective on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. StockNews.com upgraded Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Stifel Nicolaus decreased their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Finally, Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $214.40.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.